ArticleRegenerative therapy2026
Lung cancer cell-derived exosomal EHF drives M2 macrophage polarization via transcriptional activation of RNF41 to promote tumor progression.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: M2 macrophage polarization in the tumor microenvironment drives lung cancer progression. ETS homologous factor (EHF) is overexpressed in lung cancer and linked to malignancy. However, the mechanism by which EHF regulates macrophage M2 polarization in the lung cancer microenvironment remains unclear. Methods: EHF expression in lung cancer tissues was assessed via bioinformatics databases, qRT-PCR, and Western blot. Cell proliferation, glycolysis indices, apoptosis, and migration were evaluated via EdU, commercial kits, flow cytometry, and Transwell, respectively. Lung cancer cell exosomes were isolated, with their characteristics identified by transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA). Next, the binding between ring finger protein 41 (RNF41) and EHF was predicted via JASPER and verified by chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays. Results: EHF was highly expressed in lung cancer. Downregulation of EHF suppressed the malignant phenotypes of lung cancer cells and reduced M2 polarization of macrophages. Exosomes from lung cancer cells could enrich EHF and deliver it to macrophages, promoting their M2 polarization, while knockdown of EHF in exosomes reversed this effect. Mechanistically, EHF bound to the RNF41 promoter and promoted its transcription, and overexpression of RNF41 could reverse the suppressive effects of EHF silencing on macrophage M2 polarization and lung cancer progression. Conclusion: Exosomal EHF derived from lung cancer cells promoted M2 polarization of macrophages through transcriptional regulation of RNF41, thereby driving lung cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.